Philip Siberg
Chief Executive Officer
October 29, 2026
Q3 CEO presentation
Philip Siberg, CEO of Senzime, gives a market update on latest news.
Presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Regulatory PR
Senzime Q3 2026: Continued strong sensor sales and growth in all regions. Clear progress towards profitability.
Press release
Invitation to presentations of Senzime’s third quarter 2026 report
Press release
New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime’s TetraGraph and Quantitative Neuromuscular Monitoring
Financial info Q3 2026:
GROWTH IN ALL REGIONS AND STRONG SENSOR SALES. CLEAR PROGRESS TOWARDS PROFITABILITY.
The third quarter demonstrates that our initiatives to strengthen profitability are delivering clear results. We report growth across all regions, continued strong performance in recurring sensor sales, and a significantly improved gross margin. At the same time, we have continued to reduce costs and improve cash flow. We have also made several important strategic and commercial advances that strengthen our position in the global neuromuscular monitoring market.
Our target of achieving positive cash flow within the fourth quarter of 2026 remains unchanged.
30,099
KSEK, Net sales
43
%, Growth in sensor sales
70
%, Improvement in cash flow
59
%, Improvement in EBITDA
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.